Unhidea explains global investment research, selected interviews and market briefs. Explore source attribution, dates, key assumptions and the reasoning behind each article.
Johnson & Johnson management expects operational sales growth to accelerate in 2027 and says the medical devices business had rebounded in October. Longer-term growth depends on new product launches and pipeline progress, particularly expansion into solid tumors.
Goldman Sachs ·
JNJ-6143 achieved a high response rate in patients with advanced prostate cancer; data on another combination therapy for head and neck cancer also met Goldman Sachs’ expectations.
Goldman Sachs ·
Riptac showed potential for efficacy and tolerability in prostate cancer patients who had received multiple prior lines of treatment, while Rybrevant offers a new opportunity in head and neck cancer. But Johnson & Johnson already trades at a premium valuation of 21 times expected 2027 earnings per share, limiting its relative upside in JPMorgan's view.
J.P. Morgan ·
